SG11201707182WA - Immunomodulatory fusion proteins and uses thereof - Google Patents
Immunomodulatory fusion proteins and uses thereofInfo
- Publication number
- SG11201707182WA SG11201707182WA SG11201707182WA SG11201707182WA SG11201707182WA SG 11201707182W A SG11201707182W A SG 11201707182WA SG 11201707182W A SG11201707182W A SG 11201707182WA SG 11201707182W A SG11201707182W A SG 11201707182WA SG 11201707182W A SG11201707182W A SG 11201707182WA
- Authority
- SG
- Singapore
- Prior art keywords
- fusion proteins
- immunomodulatory fusion
- immunomodulatory
- proteins
- fusion
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000002519 immonomodulatory effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464452—Transcription factors, e.g. SOX or c-MYC
- A61K39/464453—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70507—CD2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562128979P | 2015-03-05 | 2015-03-05 | |
PCT/US2016/021064 WO2016141357A1 (en) | 2015-03-05 | 2016-03-04 | Immunomodulatory fusion proteins and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201707182WA true SG11201707182WA (en) | 2017-10-30 |
Family
ID=55587371
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201908203S SG10201908203SA (en) | 2015-03-05 | 2016-03-04 | Immunomodulatory Fusion Proteins And Uses Thereof |
SG11201707182WA SG11201707182WA (en) | 2015-03-05 | 2016-03-04 | Immunomodulatory fusion proteins and uses thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201908203S SG10201908203SA (en) | 2015-03-05 | 2016-03-04 | Immunomodulatory Fusion Proteins And Uses Thereof |
Country Status (16)
Country | Link |
---|---|
US (2) | US20180044404A1 (en) |
EP (1) | EP3265481A1 (en) |
JP (3) | JP6917896B2 (en) |
KR (1) | KR20170120701A (en) |
CN (1) | CN107531805A (en) |
AU (3) | AU2016226022B2 (en) |
BR (1) | BR112017018919A8 (en) |
CA (2) | CA2978186A1 (en) |
HK (1) | HK1246317A1 (en) |
IL (1) | IL254165B (en) |
MX (4) | MX2017011201A (en) |
MY (2) | MY196588A (en) |
RU (1) | RU2755227C2 (en) |
SA (1) | SA517382216B1 (en) |
SG (2) | SG10201908203SA (en) |
WO (1) | WO2016141357A1 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
EP3394092A1 (en) | 2015-12-23 | 2018-10-31 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
ES2962588T3 (en) * | 2016-03-23 | 2024-03-20 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | PD-1 and 4-1BB fusion proteins |
EP3458096A4 (en) | 2016-05-18 | 2019-11-27 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
CN117683135A (en) | 2016-07-14 | 2024-03-12 | 百时美施贵宝公司 | Antibodies against TIM3 and uses thereof |
WO2018009972A1 (en) * | 2016-07-14 | 2018-01-18 | Peter Maccallum Cancer Institute | Chimeric antigen receptor modified t cells |
US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
WO2018102761A1 (en) * | 2016-12-02 | 2018-06-07 | City Of Hope | Methods for manufacturing and expanding t cells expressing chimeric antigen receptors and other receptors |
MX2019006852A (en) * | 2016-12-22 | 2019-08-26 | Windmil Therapeutics Inc | Compositions and methods for modulating the immune system. |
CN110325205B (en) | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T cell modulating multimeric polypeptides and methods of use thereof |
WO2018129474A1 (en) | 2017-01-09 | 2018-07-12 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
CA3054955A1 (en) | 2017-03-15 | 2018-09-20 | Cue Biopharma, Inc. | Methods for modulating an immune response |
CA3055784A1 (en) * | 2017-03-17 | 2018-09-20 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
WO2018182511A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
CN110636851B (en) | 2017-03-27 | 2023-11-03 | 新加坡国立大学 | Truncated NKG2D chimeric receptor and use thereof in natural killer cell immunotherapy |
JP7262440B2 (en) | 2017-08-02 | 2023-04-21 | フェインズ セラピューティクス,インコーポレーテッド | Anti-CD47 antibody and uses thereof |
CA3072329A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
US10960071B2 (en) | 2017-08-07 | 2021-03-30 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
JP2021500855A (en) * | 2017-09-07 | 2021-01-14 | キュー バイオファーマ, インコーポレイテッド | Antigen-presenting polypeptides and how to use them |
WO2019055862A1 (en) | 2017-09-14 | 2019-03-21 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
WO2019090355A1 (en) * | 2017-11-06 | 2019-05-09 | Children's National Medical Center | Cells expressing antibodies and methods of treatment using the same |
US11866731B2 (en) | 2017-11-10 | 2024-01-09 | Chineo Medical Technology Co., Ltd | Modified immune cells and uses thereof |
CN111886241A (en) | 2018-01-09 | 2020-11-03 | 库尔生物制药有限公司 | Multimeric T cell modulating polypeptides and methods of use thereof |
MX2020014031A (en) * | 2018-06-21 | 2021-05-12 | Shattuck Labs Inc | Heterodimeric proteins and uses thereof. |
KR102261407B1 (en) * | 2018-10-10 | 2021-06-08 | 한국화학연구원 | Chimeric antigen receptors targeting Herpesvirus entry mediator |
TW202039542A (en) | 2018-12-19 | 2020-11-01 | 美商庫爾生物製藥有限公司 | Multimeric t-cell modulatory polypeptides and methods of use thereof |
GB201900858D0 (en) * | 2019-01-22 | 2019-03-13 | Price Nicola Kaye | Receptors providing targeted costimulation for adoptive cell therapy |
SG11202109057XA (en) | 2019-03-05 | 2021-09-29 | Nkarta Inc | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
SG11202109745PA (en) | 2019-03-11 | 2021-10-28 | Hutchinson Fred Cancer Res | High avidity wt1 t cell receptors and uses thereof |
WO2020190771A1 (en) * | 2019-03-15 | 2020-09-24 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric adaptor and kinase signaling proteins and their use in immunotherapy |
JP2022526504A (en) * | 2019-03-21 | 2022-05-25 | オーエヌケー セラピューティクス リミテッド | Modified immune effector cells with increased resistance to cell death |
CN115666594A (en) * | 2019-11-29 | 2023-01-31 | 苏州诺沃泰医药科技有限公司 | Application of CART cells in preparation of medicine for treating cancer |
WO2021205175A1 (en) * | 2020-04-09 | 2021-10-14 | Autolus Limited | Molecule |
CA3174812A1 (en) * | 2020-04-09 | 2021-10-14 | Autolus Limited | Cell |
GB202101491D0 (en) * | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
WO2021231376A2 (en) | 2020-05-12 | 2021-11-18 | Cue Biopharma, Inc. | Multimeric t-cell modulatory polypeptides and methods of use thereof |
BR112022023371A2 (en) * | 2020-05-22 | 2022-12-20 | Chongqing Prec Biotech Co Ltd | FUSION PROTEIN FOR REVERSING THE TUMOR MICROENVIRONMENT, EXPRESSION VECTOR, IMMUNE CELL, TUMOR IMMUNOSUPPRESSION-RESISTANT CHIMERIC ANTIGEN RECEPTOR, NUCLEIC ACID SEQUENCE, METHOD FOR PREPARING AN IMMUNE CELL, PHARMACEUTICAL COMPOSITION, AND, USE OF THE PHARMACEUTICAL COMPOSITION |
WO2022020745A1 (en) * | 2020-07-23 | 2022-01-27 | Emory University | Galectin-9 specific binding agents for use in treating cancer |
WO2022246041A2 (en) * | 2021-05-20 | 2022-11-24 | Achelois Biopharma, Inc. | Compositions and methods for multivalent surface display on enveloped particles |
CN117813106A (en) * | 2021-05-20 | 2024-04-02 | 阿奇洛伊斯生物制药公司 | Immune checkpoint multivalent particle compositions and methods of use |
WO2022266192A1 (en) | 2021-06-16 | 2022-12-22 | Instil Bio, Inc. | Receptors providing targeted costimulation for adoptive cell therapy |
WO2023288278A1 (en) | 2021-07-16 | 2023-01-19 | Instil Bio (Uk) Limited | Chimeric molecules providing targeted costimulation for adoptive cell therapy |
CN113621077B (en) * | 2021-09-02 | 2023-01-31 | 山东大学 | TIM-3/CD28 fusion protein and CAR-T cell modified by fusion protein |
WO2023150801A2 (en) * | 2022-02-07 | 2023-08-10 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Recombinant proteins that stimulate an immune response in the presence of naturally inhibitory ligand binding |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
DK1489097T3 (en) | 1994-01-11 | 2012-01-09 | Dyax Corp | Inhibitors of human plasmin derived from kunitz domains and nucleic acids encoding the same |
AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
DE602005022595D1 (en) | 2004-06-29 | 2010-09-09 | Immunocore Ltd | A MODIFIED T-CELL RECEPTOR EXPRESSING CELLS |
CA2594356C (en) | 2005-01-05 | 2018-07-17 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H. | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
EP2198022B1 (en) | 2007-09-24 | 2024-03-06 | University Of Zurich | Designed armadillo repeat proteins |
US9163258B2 (en) * | 2010-07-23 | 2015-10-20 | Fred Hutchinson Cancer Research Center | Method for the treatment of obesity |
BR122021026173B1 (en) * | 2010-12-09 | 2023-12-05 | The Trustees Of The University Of Pennsylvania | PHARMACEUTICAL COMPOSITION |
AU2012230780B2 (en) * | 2011-03-23 | 2016-10-27 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
CN114835823A (en) | 2011-07-29 | 2022-08-02 | 宾夕法尼亚大学董事会 | Transducible co-stimulatory receptors |
JP6074435B2 (en) | 2011-10-26 | 2017-02-01 | ナショナル キャンサー センター | Mutant CTLA4 gene-transferred T cell and anticancer immunotherapeutic composition containing the same |
WO2013123061A1 (en) * | 2012-02-13 | 2013-08-22 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
EP2943565B1 (en) * | 2013-01-14 | 2018-03-28 | Fred Hutchinson Cancer Research Center | Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse |
JP6712261B2 (en) * | 2014-08-04 | 2020-06-24 | フレッド ハッチンソン キャンサー リサーチ センター | WT-1 specific T cell immunotherapy |
DK3180363T3 (en) * | 2014-08-15 | 2019-11-04 | Merck Patent Gmbh | SIRP-ALPHA-IMMUNOGLOBULIN FUSION PROTEINS |
EP3247808B1 (en) * | 2015-01-21 | 2021-05-05 | Fred Hutchinson Cancer Research Center | Point-of-care and/or portable platform for gene therapy |
EP3394092A1 (en) * | 2015-12-23 | 2018-10-31 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
US10188749B2 (en) * | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
CN109312304A (en) * | 2016-04-20 | 2019-02-05 | 弗雷德哈钦森癌症研究中心 | Immune regulative IL2R fusion protein and application thereof |
CA3055784A1 (en) * | 2017-03-17 | 2018-09-20 | Fred Hutchinson Cancer Research Center | Immunomodulatory fusion proteins and uses thereof |
-
2016
- 2016-03-04 SG SG10201908203S patent/SG10201908203SA/en unknown
- 2016-03-04 US US15/555,951 patent/US20180044404A1/en not_active Abandoned
- 2016-03-04 BR BR112017018919A patent/BR112017018919A8/en active Search and Examination
- 2016-03-04 CA CA2978186A patent/CA2978186A1/en active Pending
- 2016-03-04 RU RU2017133637A patent/RU2755227C2/en active
- 2016-03-04 CN CN201680023758.4A patent/CN107531805A/en active Pending
- 2016-03-04 CA CA3177938A patent/CA3177938A1/en active Pending
- 2016-03-04 WO PCT/US2016/021064 patent/WO2016141357A1/en active Application Filing
- 2016-03-04 SG SG11201707182WA patent/SG11201707182WA/en unknown
- 2016-03-04 MY MYPI2021007596A patent/MY196588A/en unknown
- 2016-03-04 EP EP16711081.6A patent/EP3265481A1/en active Pending
- 2016-03-04 MX MX2017011201A patent/MX2017011201A/en unknown
- 2016-03-04 AU AU2016226022A patent/AU2016226022B2/en active Active
- 2016-03-04 MY MYPI2017001281A patent/MY189195A/en unknown
- 2016-03-04 JP JP2017546715A patent/JP6917896B2/en active Active
- 2016-03-04 KR KR1020177027794A patent/KR20170120701A/en not_active Application Discontinuation
-
2017
- 2017-08-27 IL IL254165A patent/IL254165B/en unknown
- 2017-08-30 SA SA517382216A patent/SA517382216B1/en unknown
- 2017-08-31 MX MX2022006004A patent/MX2022006004A/en unknown
- 2017-08-31 MX MX2022006002A patent/MX2022006002A/en unknown
- 2017-08-31 MX MX2022006006A patent/MX2022006006A/en unknown
-
2018
- 2018-05-03 HK HK18105732.2A patent/HK1246317A1/en unknown
-
2020
- 2020-05-01 JP JP2020081118A patent/JP7026161B2/en active Active
- 2020-09-30 AU AU2020244495A patent/AU2020244495B2/en active Active
-
2021
- 2021-02-03 US US17/166,903 patent/US20210403532A1/en active Pending
- 2021-09-15 JP JP2021150184A patent/JP7441201B2/en active Active
-
2022
- 2022-11-16 AU AU2022271411A patent/AU2022271411A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1246317A1 (en) | Immunomodulatory fusion proteins and uses thereof | |
IL265657A (en) | Immunomodulatory fusion proteins | |
HK1250044A1 (en) | Gitrl fusion proteins and uses thereof | |
HRP20190028T1 (en) | Interleukin-2 fusion proteins and uses thereof | |
IL262366A (en) | Cd80 variant immunomodulatory proteins and uses thereof | |
ZA201808284B (en) | Gdf15 fusion proteins and uses thereof | |
HK1244019A1 (en) | Fusion proteins | |
IL249327A0 (en) | Mic-1 fusion proteins and uses thereof | |
GB201509062D0 (en) | OX40L fusion proteins and uses thereof | |
GB2570063B (en) | Fusion protein and applications thereof | |
IL273626A (en) | Immunomodulatory fusion proteins | |
GB2543713B (en) | Polymeric proteins and uses thereof | |
EP3237452A4 (en) | Fusion proteins and methods thereof | |
GB201602850D0 (en) | Fusion proteins | |
HK1251456A1 (en) | Immunoglobulin fusion proteins and uses thereof | |
GB201617925D0 (en) | Proteins and uses |